Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | TACR3 | P29371 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | EED | O75530 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8237687 | 0.85 | ACKR3 (0.57) | HSD11B1TACR3 | |
| SCHEMBL6214983 | 0.85 | ACKR3 (0.57) | HSD11B1TACR3 | |
| SCHEMBL14263092 | 0.83 | TACR3 (0.59) | L3MBTL1HSD11B1TACR3ALDH1A1MEN1 | |
| SCHEMBL31324479 | 0.83 | TACR3 (0.62) | HSD11B1TACR3ALDH1A1MEN1KMT2A | |
| SCHEMBL4144887 | 0.83 | SMN1; SMN2 (0.51) | L3MBTL1ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL20063079 | 0.83 | HSD11B1 (0.49) | L3MBTL1HSD11B1TACR3EEDRAB9A | |
| SCHEMBL22869197 | 0.83 | SMN1; SMN2 (0.56) | MEN1KMT2ANPC1CYP2D6CYP2C9 | |
| SCHEMBL13107004 | 0.82 | HCRTR1 (0.52) | ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL22048483 | 0.81 | TACR3 (0.59) | HSD11B1TACR3ALDH1A1MEN1KMT2A | |
| SCHEMBL21138804 | 0.81 | HSD11B1 (0.62) | HSD11B1TACR3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-1140834-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035877-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | L3MBTL1 4873/4885HSD11B1 478/4885TACR3 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.